NewTimeSpace News: Harbin Bank announced on 16 July that the qualification of Mr. Du Xiaoquan to serve as the Company’s Non-executive Director has been approved by the Heilongjiang Regulatory Bureau of the State Administration of Financial Supervision, with effect from 14 July.
NewTimeSpace News: Hengrui Pharmaceuticalsannounced on 16 July that its subsidiary Fujian Shengdi has received the Clinical Trial Approval Notice for Injection HRS9531 issued by the National Medical Products Administration (NMPA).
By the close of trading on Jul 16, 2026, BONJOUR HOLD(00653.HK) saw a gain of 22% in its share price, closing at HK cents 6.1. During the session, it reached an intraday high of HK cents 6.3 and touched an intraday low of HK cents 4.9.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jul 16, 2026, JOLIMARK(02028.HK) saw a loss of 29.41% in its share price, closing at HKD 1.8. During the session, it reached an intraday high of HKD 2.61 and touched an intraday low of HKD 1.69.
NewTimeSpace News: GHPC (01847.HK) announced on 16 July that Mr. Wang Junjie has been appointed Chief Engineer of the Company with tenure running until the expiry of the term of the third Board of Directors. A 40-year-old senior engineer, Mr. Wang joined the Group in 2017, has received multiple technical honours and holds three invention patents.
NewTimeSpace News: INNOCARE (09969.HK) announced on 16 July that its TYK2 inhibitor Soficitinib (ICP-332) hit the primary endpoint in the Phase II segment of adaptive Phase II/III trial for adult patients with non-segmental vitiligo. F-VASI dropped roughly 39%-41% at Week 24 versus baseline, versus only 2.2% in placebo arm with statistically significant differences. The candidate demonstrated favourable safety profile, and the Company will advance to Phase III and communicate with regulators. Risks associated with clinical development exist.
NewTimeSpace News: Henlius (02696.HK) announced on 16 July that HLX18, its self-developed biosimilar of nivolumab (recombinant anti-PD-1 humanised monoclonal antibody injection), has administered the first patient in China in its global multi-centre Phase I trial for resected solid tumours. The Company plans to expand the trial to the US and other regions when conditions permit. Targeting PD-1, the reference drug recorded global sales of approximately USD11.785 billion in 2025 per IQVIA data. The Company cautions there is no guarantee of successful development and commercialisation of HLX18.
NewTimeSpace News: BIDU-SW (09888.HK) announced that the Board of Directors has approved a proposal to voluntarily convert its listing status to dual primary listing on the HKEX Main Board in accordance with HKEX guidance letters, with conversion expected to take effect within the current year. Upon completion, Baidu will be dual-primary listed on HKEX Main Board and Nasdaq Global Select Market.
NewTimeSpace News: On 16 July 2026, BIDU-SW(09888.HK) strengthened in the afternoon session. As of 15:44, its intraday price stood at HK$110.10, representing a 2.42% gain. Baidu’s Apollo Go has fulfilled more than 22 million cumulative service orders as of April, with its business footprint covering 27 cities worldwide.
NewTimeSpace (newtimespace.com) reported that on July 16, 2026, the semiconductor theme in Hong Kong stocks fluctuated weaker, while SMIC (00981.HK) edged slightly higher. As of 13:30, the stock was quoted at HKD 76.450, up a marginal 0.20%.
NewTimeSpace News: FANTASIA (01777.HK) announced that the restructuring condition requiring regulatory approval from the National Development and Reform Commission (NDRC) has been satisfied on 16 July 2026. The Company has designated 30 July 2026 as the restructuring effective date, subject to the satisfaction or waiver of all remaining restructuring conditions in accordance with the terms of the schemes.
NewTimeSpace News: UNITED LAB (03933.HK) announced that its subsidiary United Biotech received US$13.5 million milestone payment (after Danish withholding tax) from Novo Nordisk for completing global Phase II clinical trial of UBT251 injection for overweight and obesity indication. Under the previously executed exclusive licence agreement, United Biotech is eligible for potential milestone payments of up to US$1.8 billion plus tiered royalties on sales.
NewTimeSpace (newtimespace.com) reported that on July 16, 2026, the humanoid robot theme fluctuated, with UBTECH (09880.HK) strengthening in choppy trading. As of 13:10, the stock was quoted at HKD 88.450, up 3.15%.
NewTimeSpace News: SSY GROUP (02005.HK) announced that the Group has obtained the drug production registration approval issued by NMPA for Choline Fenofibrate Sustained-release Capsule (135mg). Classified as Category 4 chemical drug, it is deemed to have passed consistency evaluation. The product is mainly applied to reduce triglyceride levels in patients with severe hypertriglyceridemia and treat primary hypercholesterolemia.
NewTimeSpace News: JENSCARE-B (09877.HK) announced that LuX-Valve Plus, its self-developed transcatheter tricuspid valve replacement system, has recently completed the first subject implantations in the FDA-approved US pivotal registration trial, marking a breakthrough progress in its US clinical programme. The trial will conduct head-to-head randomised control against Edwards Lifesciences’ EVOQUE system.
NewTimeSpace (newtimespace.com) News, GEEKPLUS-W(02590.HK) will spend HKD 12.11 million to repurchase 1.2 million shares on Jul 15, 2026.
